Thanks for a Successful
Advanced Biologic Development Summit

Check Back for the 2018 Event Synopsis

The Advanced Biologic Development Summit

Northeastern University, the Barnett Institute, and Cambridge-based BioAnalytix were pleased to host the inaugural Advanced Biologic Development Summit. A special thanks to our 2018 Keynote Speakers and Panelists for their engaging presentations and inspiring ideas.

In the weeks to come, we will provide a detailed synopsis of presentations and ideas shared at this year’s event that were a great first step to help define, catalyze, and advance translational research and industry-leading standards at the intersection of analytic technologies, data analysis, and biopharmaceutical development. The topic of integrating characterization, CMC, and clinical program data and analysis has generated significant interest, and we look forward to continuing the discussion throughout the year.

We hope to see you at next year’s Summit, and in the meantime, we welcome you to share your testimonial, comments, questions or ideas for planning below:

Subscribe for Summit Updates

* indicates required

A Special Thanks to Our 2018 Presenters

Steve Kozlowski

Steve Kozlowski, MD

Keynote Speaker

Director, Office of Biotechnology Products, US Food and Drug Administration

Wassim Nashabeh

Wassim Nashabeh, PhD

Keynote Speaker

Vice President, Regulatory Policy and International Operations, Roche Pharmaceutical Group

Patrick Swann

Patrick Swann, PhD

Panelist

Vice President, Quality Science and Technology, Amgen
Former Vice President, CMC Regulatory Affairs, Biogen and Deputy Director, Division of Monoclonal Antibodies, US Food and Drug Administration

Katy Stein

Katy Stein, PhD

Panelist

Principal, Kathryn Stein Consulting
Former Director, Division of Monocolonal Antibodies, US Food and Drug Administration and Senior Vice President, Product Development and Regulatory Affairs, Macrogenics

Patrick Swann

Pamela M. Klein, MD

Panelist

Principal, PMK BioResearch
Former Chief Medical Officer, Intellikine (acquired by Millennium/Takeda) and Vice President, Development, Genentech